Cardiac fibrosis is a critical component of heart disease, involving the transformation of cardiac fibroblasts (CFs) into myofibroblasts (MFs) following injury. This process leads to pathological remodeling, characterized by chamber dilation, cardiomyocyte hypertrophy, and apoptosis, ultimately resulting in heart failure. Despite its importance, the origins and roles of CFs remain poorly understood, hindering the development of effective therapies. This review summarizes current knowledge on CF origins, mediators, signaling pathways, and novel therapeutic strategies targeting cardiac fibrosis. CFs are essential for maintaining the extracellular matrix (ECM) in the heart, but upon injury, they transform into MFs, which secrete ECM proteins to promote fibrosis. This process is influenced by various factors, including TGF-β, AngII, and ET-1, which activate signaling pathways leading to fibroblast activation and ECM deposition. The role of CFs in injury is complex, with some contributing to adaptive responses while others promote pathological remodeling. The sources of activated CFs include resident fibroblasts, cells of vascular origin, hematopoietic cells, and pericytes. Current research focuses on identifying molecular markers for CFs and MFs, such as DDR2, FSP1, Thy1, vimentin, TCF21, PDGFRα, and PDGFRβ. These markers help in understanding the origins and functions of CFs, but their expression in other cell types complicates their use. Advances in lineage tracing and transcriptomics are improving our understanding of CF biology. Therapeutic targets include signaling pathways such as TGF-β, AngII, and ET-1, which are involved in fibroblast activation and ECM deposition. Inhibitors of these pathways, including TGF-β receptor ALK5, AngII receptor blockers, and endothelin antagonists, are being investigated for their potential to reduce fibrosis. Additionally, the RhoA-MRTF-SRF signaling pathway and TRP channels are emerging as important targets for antifibrotic therapies. Overall, understanding the complex roles of CFs in cardiac fibrosis is crucial for developing effective treatments. Current research highlights the need for further investigation into the molecular mechanisms underlying fibrosis and the development of targeted therapies to mitigate its pathological effects.Cardiac fibrosis is a critical component of heart disease, involving the transformation of cardiac fibroblasts (CFs) into myofibroblasts (MFs) following injury. This process leads to pathological remodeling, characterized by chamber dilation, cardiomyocyte hypertrophy, and apoptosis, ultimately resulting in heart failure. Despite its importance, the origins and roles of CFs remain poorly understood, hindering the development of effective therapies. This review summarizes current knowledge on CF origins, mediators, signaling pathways, and novel therapeutic strategies targeting cardiac fibrosis. CFs are essential for maintaining the extracellular matrix (ECM) in the heart, but upon injury, they transform into MFs, which secrete ECM proteins to promote fibrosis. This process is influenced by various factors, including TGF-β, AngII, and ET-1, which activate signaling pathways leading to fibroblast activation and ECM deposition. The role of CFs in injury is complex, with some contributing to adaptive responses while others promote pathological remodeling. The sources of activated CFs include resident fibroblasts, cells of vascular origin, hematopoietic cells, and pericytes. Current research focuses on identifying molecular markers for CFs and MFs, such as DDR2, FSP1, Thy1, vimentin, TCF21, PDGFRα, and PDGFRβ. These markers help in understanding the origins and functions of CFs, but their expression in other cell types complicates their use. Advances in lineage tracing and transcriptomics are improving our understanding of CF biology. Therapeutic targets include signaling pathways such as TGF-β, AngII, and ET-1, which are involved in fibroblast activation and ECM deposition. Inhibitors of these pathways, including TGF-β receptor ALK5, AngII receptor blockers, and endothelin antagonists, are being investigated for their potential to reduce fibrosis. Additionally, the RhoA-MRTF-SRF signaling pathway and TRP channels are emerging as important targets for antifibrotic therapies. Overall, understanding the complex roles of CFs in cardiac fibrosis is crucial for developing effective treatments. Current research highlights the need for further investigation into the molecular mechanisms underlying fibrosis and the development of targeted therapies to mitigate its pathological effects.